Q-omics provides the consensus-scored MYO1H profile across patient tissues and cancer cell-line models. MYO1H expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYO1H is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MYO1H RNA expression shows 17,132 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where MYO1H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO1H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO1H survival associations across molecular data types. MYO1H RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO1H RNA expression–survival associations across cancer types. High MYO1H expression shows unfavorable associations in LGG, ACC and LIHC, but favorable associations in HNSC, LUAD and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYO1H RNA expression.
This table summarizes MYO1H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MYO1H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO1H shows lower tumor expression in THCA, KIRP and BRCA and higher tumor expression in KICH, LIHC and CHOL. The THCA box plot shows higher MYO1H RNA expression in normal versus tumor tissue (log2 FC = −0.480, t-test p < 0.001).
This table shows molecular features associated with MYO1H in patient tissues and cancer cell lines. In patient samples, MYO1H shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO1H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
